D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

P

PolyPid

Status and phase

Completed
Phase 2

Conditions

Colon Surgery
Post-Op Infection
Abdominal Surgery

Treatments

Drug: D_PLEX
Other: Standard of Care (SoC)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03633123
D-PLEX 310

Details and patient eligibility

About

Subjects who are planned to undergo an abdominal (colon) surgery and who will meet the study entry criteria will be randomly divided into 2 groups: for half D-PLEX will be administered concomitantly with the standard of care (SOC). The other half will receive the Standard of Care treatment. Following the surgery subjects will be followed up for additional 5 visits, at least half are in line with the routine practice of surgery Follow-Ups. Visits will include patient safety and wound assessments.

Full description

D-PLEX is a new formulation of extended controlled release of Doxycycline in the applied area for about 30 days. This study is aimed to assess the safety and efficacy of D-PLEX in prevention of post abdominal surgery incisional infection. Eligible and willing subjects will be randomly divided, in a single-blinded manor into 2 study arms D-PLEX with SOC or SOC alone. D-PLEX will be applied during the surgery at the final stage of incision closure. All patients will be followed up for additional 5 visits over 2 months, for safety and incisional wound assessment. This will include blood tests for hematology, chemistry and PK (for some only) as well as physicians assessment of the incisional wound.

Enrollment

200 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Subjects undergoing elective abdominal colon surgery involving resection and anastomosis or a stoma. 2. Male or non-pregnant female Female of childbearing potential should have a negative serum pregnancy test prior to index procedure and agree to use a highly effective method of contraception consistently and correctly for the duration of the study. 3. Subjects who sign a written informed consent 4. Subjects who are willing and able to participate and meet all study requirements. 5. Survival expectancy of at least 60 days post randomization.

Exclusion criteria

1. Subjects scheduled for abdominal surgery which is classified as emergency. 2. Subjects with any preoperative active infection that is currently being treated with antibiotics. 3. Subjects receiving any antibiotic therapy in the past 4 weeks prior to enrolment besides prophylaxis or antibiotic for the treatment of the disease that consists the indication for surgery. 4. Patients undergoing concomitant additional procedures besides colon resection surgery, e.g. Hyper-thermic Intraperitoneal Chemotherapy, liver resection etc. Female sterilization surgery (i.e. salpingo-oophorectomy, hysterectomy etc.), or involvement of a small bowel procedure or Cholecystectomy may be allowed, pending an advanced consultation and approval from the sponsor. 5. Subject received chemotherapy within the last 4 weeks of surgery, or radiation for colorectal cancer to the abdomen area, prior to the planned abdominal surgery (neo- adjuvant treatment). 6. Subjects that received oral or IV doxycycline during the past 4 weeks prior to screening. 7. Subjects with known sensitivity to doxycycline and/or to the tetracycline family of drugs or to the D-PLEX's excipients. 8. Subjects with known allergies to more than 3 substances (an allergy questionnaire will be filled in during the screening process). 9. Subjects with a history of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intravenous steroids/intramuscular epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic/hypersensitivity reactions. 10. Subjects with uncontrolled Asthma (GINA III-IV). 11. Subjects with End Stage Renal Disease \[Chronic Kidney Disease (CKD) stage 5\]. 12. Subjects with chronic urticaria. 13. Subjects diagnosed with severe neurological/cardiac events within the past 1 year prior to randomization. 14. Subjects that undergone any abdominal surgery and current planned surgery involves re-opening the scar of prior abdominal surgery. 15. Any subject with active malignancy or with malignancy that has not been in complete remission for at least 5 years. Excluding: * subjects with potentially resectable non-metastatic colorectal cancer which consists the indication for surgery. In addition, * patients Patients who have had carcinoma in situ of the cervix, squamous cell carcinoma of the skin and basal cell carcinoma of the skin * Non-violent cancer that does not require treatment 4 weeks prior to, and throughout the entire study duration will be eligible. 16. Subjects with other concurrent severe and/or uncontrolled medical condition that could compromise participation in the study (e.g. non-GI active infection, uncontrolled diabetes, uncontrolled hypertension, congestive heart failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, uncompensated cirrhosis, active upper gastrointestinal (GI) tract ulceration). 17. Psychiatric, addictive, or any other disorder that compromises ability to provide informed consent for participation in this study. 18. Chronic alcoholic or drug abuse subjects. 19. Pregnant or breast-feeding women or women of childbearing age who refuse or prohibited of using an effective contraceptive method of birth control (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) throughout study participation including safety follow-up period. 20. Subjects that received any investigational drug within 30 days or 5½ half-lives of enrollment to the study (whichever is longer). 21. Subjects participating in any other interventional studies. 22. In the opinion of investigator, subject is not eligible to participate in the study and/or to comply with protocol requirements (e.g. due to a cognitive or medical condition).

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

200 participants in 2 patient groups

Standard of Care (SoC)
Other group
Description:
SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
Treatment:
Other: Standard of Care (SoC)
D-PLEX + SoC
Experimental group
Description:
D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
Treatment:
Other: Standard of Care (SoC)
Drug: D_PLEX

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems